republic-os/legislation/us/states/in/2024/sb-273.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	Biomarker testing coverage.	Requires a health plan (which includes a policy of accident and sickness insurance, a health maintenance organization contract, the Medicaid risk based managed care program, and a state employee health plan) to provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when biomarker testing is supported by medical and scientific evidence. Requires the office of Medicaid policy and planning to provide biomarker testing as a Medicaid program service, and to apply to the United States Department of Health and Human Services for approval of any waiver necessary under the federal Medicaid program for the purpose of providing biomarker testing. Provides that coverage is not required for biomarker testing for screening purposes. Provides that if a prior authorization requirement applies to biomarker testing, the health plan or a third party acting on behalf of the health plan must: (1) approve or deny a request for prior authorization; and (2) notify the covered individual of the approval or denial; in not more than five business days in the case of a nonurgent request or in not more than 48 hours in the case of an urgent request. Requires the office of the secretary of family and social services to report certain information to the budget committee on Medicaid reimbursement rates provided for biomarker testing.	us/states/in	Indiana General Assembly	2024	SB 273	Indiana SB 273 (2024)	bill	AGENCIES; Family and Social Services Administration (FSSA) HEALTH; Generally HEALTH; Medicaid INSURANCE; Health Insurance STATE GOVERNMENT; Federal Funding	enacted	Brad Barrett Ed Charbonneau Jean Leising Vaneta Becker	4	31	2	2024-01-11	2024-03-11	openstates	ocd-bill/8dae05ee-aee9-41e9-a1ba-bee1b3d14fec	https://api.iga.in.gov/2024/bills/sb0273	d790cfc08f45d3f623486cdaca32ffdb01407ae4520a1e9d4879044b21ce365d	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-in

Indiana SB 273 (2024) — Biomarker testing coverage.

Requires a health plan (which includes a policy of accident and sickness insurance, a health maintenance organization contract, the Medicaid risk based managed care program, and a state employee health plan) to provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when biomarker testing is supported by medical and scientific evidence. Requires the office of Medicaid policy and planning to provide biomarker testing as a Medicaid program service, and to apply to the United States Department of Health and Human Services for approval of any waiver necessary under the federal Medicaid program for the purpose of providing biomarker testing. Provides that coverage is not required for biomarker testing for screening purposes. Provides that if a prior authorization requirement applies to biomarker testing, the health plan or a third party acting on behalf of the health plan must: (1) approve or deny a request for prior authorization; and (2) notify the covered individual of the approval or denial; in not more than five business days in the case of a nonurgent request or in not more than 48 hours in the case of an urgent request. Requires the office of the secretary of family and social services to report certain information to the budget committee on Medicaid reimbursement rates provided for biomarker testing.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Enrolled Senate Bill (S) (committee substitute) — source
2. Introduced Senate Bill (S) (committee substitute) — source
3. Senate Bill (H) (committee substitute) — source
4. Senate Bill (S) (committee substitute) — source

Votes

• SB 273 - Barrett - 3rd Reading — 94–0 (pass) · lower
• SB 273 - Charbonneau - 3rd Reading — 47–1 (pass) · upper

Sponsors

• Brad Barrett — primary (person)
• Ed Charbonneau — primary (person)
• Jean Leising — primary (person)
• Vaneta Becker — primary (person)
• Edward Clere — cosponsor (person)
• Eric Bassler — coauthor (person)
• Fady Qaddoura — coauthor (person)
• Gregory Porter — cosponsor (person)
• J.D. Ford — coauthor (person)
• Lonnie Randolph — coauthor (person)
• Matt Lehman — cosponsor (person)
• Mike Bohacek — coauthor (person)
• Shelli Yoder — coauthor (person)
• Susan Glick — coauthor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2024-01-11 First reading: referred to Committee on Insurance and Financial Institutions reading-1, referral-committee
• 2024-01-11 Authored by Senators Charbonneau and Becker
• 2024-01-16 Senator Qaddoura added as coauthor
• 2024-01-18 Senator Leising added as third author
• 2024-01-18 Committee report: amend do pass adopted; reassigned to Committee on Appropriations committee-passage, referral-committee
• 2024-01-22 Senator Bohacek added as coauthor
• 2024-01-23 Senator Bassler added as coauthor
• 2024-01-25 Senator Glick added as coauthor
• 2024-02-01 Senator Ford J.D. added as coauthor
• 2024-02-01 Senator Randolph added as coauthor
• 2024-02-01 Senator Yoder added as coauthor
• 2024-02-01 Committee report: amend do pass, adopted committee-passage
• 2024-02-05 Second reading: ordered engrossed reading-2
• 2024-02-06 Third reading: passed; Roll Call 142: yeas 47, nays 1 passage, reading-3, reading-3
• 2024-02-06 House sponsor: Representative Barrett
• 2024-02-07 Referred to the House referral
• 2024-02-12 First reading: referred to Committee on Insurance reading-1, referral-committee
• 2024-02-13 Representative Clere added as cosponsor
• 2024-02-15 Representative Porter added as cosponsor
• 2024-02-15 Representative Lehman added as cosponsor
• 2024-02-15 Referred to the Committee on Ways and Means pursuant to House Rule 127
• 2024-02-15 Committee report: do pass, adopted committee-passage
• 2024-02-22 Committee report: do pass, adopted committee-passage
• 2024-02-26 Second reading: ordered engrossed reading-2
• 2024-02-27 Third reading: passed; Roll Call 236: yeas 94, nays 0 passage, reading-3, reading-3
• 2024-02-28 Returned to the Senate without amendments receipt
• 2024-03-04 Signed by the President Pro Tempore passage
• 2024-03-07 Signed by the Speaker passage
• 2024-03-08 Signed by the President of the Senate passage
• 2024-03-11 Signed by the Governor executive-signature
• 2024-03-11 Public Law 37 became-law

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/8dae05ee-aee9-41e9-a1ba-bee1b3d14fec. Confidence: reported (aggregated from official Indiana legislature records).